AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22676840 — intervention group
Group type: COMPARATOR
Intervention: No exposure to campaign messages
Number of subjects: 0
Study 20659103 — intervention group
Group type: EXPERIMENTAL
Intervention: 45° seated position
Number of subjects: 40
Study 20659103 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 40
Study 17980179 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 0
Study 17980179 — intervention group
Group type: COMPARATOR
Intervention: Scheduled intermittent intravenous (i.v.) hydromorphone
Number of subjects: 0
Study 17980179 — intervention group
Group type: COMPARATOR
Intervention: Scheduled intermittent subcutaneous (s.q.) hydromorphone
Number of subjects: 0
Study 15741468 — intervention group
Group type: EXPERIMENTAL
Intervention: Errorless learning
Number of subjects: 60
Study 15741468 — intervention group
Group type: COMPARATOR
Intervention: Symptom management
Number of subjects: 60
Study 11894727 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive physical therapy (3.6 hours/week)
Number of subjects: 88
Study 11894727 — intervention group
Group type: COMPARATOR
Intervention: Control group (1.9 hours/week)
Number of subjects: 88
Study 10622051 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia antigen positive in patients with non-bacterial prostatitis
Number of subjects: 55
Study 10622051 — intervention group
Group type: COMPARATOR
Intervention: Chlamydia antigen positive in control group
Number of subjects: 55
Study 10622051 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with doxycycline 100 mg twice daily for 10 days
Number of subjects: 55
Study 7865201 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental acceptance of proposed aversive behavioral intervention
Number of subjects: 0
Study 7865201 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental rejection of proposed aversive behavioral intervention
Number of subjects: 0
Study 7865201 — intervention group
Group type: EXPERIMENTAL
Intervention: Judges' consideration of client's rights
Number of subjects: 0
Study 2913892 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily theophylline preparation
Number of subjects: 16
Study 2913892 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily theophylline preparation
Number of subjects: 16
Study 132901 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tetracycline hydrochloride and orally administered lactose capsules
Number of subjects: 75
Study 132901 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered tetracycline hydrochloride and topically applied placebo liquid
Number of subjects: 75
Study 132901 — intervention group
Group type: COMPARATOR
Intervention: Topically applied placebo liquid and orally administered tetracycline hydrochloride
Number of subjects: 75
Study 31699436 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 35
Study 31699436 — intervention group
Group type: COMPARATOR
Intervention: Epidural (EPI)
Number of subjects: 35
Study 31699436 — intervention group
Group type: COMPARATOR
Intervention: Patient-Controlled Analgesia (PCA)
Number of subjects: 35
Study 30696491 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality gait training (VRT)
Number of subjects: 50
Study 30696491 — intervention group
Group type: COMPARATOR
Intervention: Non-virtual reality gait training (non-VRT)
Number of subjects: 50
Study 27908689 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 genetic variants (rs11583680, rs11591147, rs2479409, rs11206510) scaled to 1 mmol/L lower LDL cholesterol
Number of subjects: 556000
Study 25181297 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for regular past tense, one-hour play-based sessions, once weekly for eight weeks
Number of subjects: 5
Study 25181297 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for regular past tense
Number of subjects: 5
Study 23458447 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (TISSEEL) applied to anastomoses
Number of subjects: 57
Study 23458447 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrin glue)
Number of subjects: 57
Study 21809068 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser surgery with biostimulation (Er:YAG laser, 200 mJ, 20 Hz, Nd:YAG laser for biostimulation)
Number of subjects: 20
Study 21809068 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 20
Study 19019342 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified AMT suturing technique (group 1, 21 patients)
Number of subjects: 39
Study 19019342 — intervention group
Group type: COMPARATOR
Intervention: Standard AMT suturing to the cornea (group 2, 18 patients)
Number of subjects: 39
Study 17026815 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1250 mg/m² on days 1 and 8 plus carboplatin AUC 5 on day 1
Number of subjects: 158
Study 17026815 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin AUC 2.5 on days 1 and 8
Number of subjects: 158
Study 12928833 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 degrees head-down bed rest for 14 days
Number of subjects: 11
Study 11126695 — intervention group
Group type: EXPERIMENTAL
Intervention: Megatrial interventions (specific interventions not mentioned)
Number of subjects: 0
Study 11126695 — intervention group
Group type: COMPARATOR
Intervention: Randomised treatment allocation
Number of subjects: 0
Study 11126695 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-scale randomised controlled clinical trials (RCT)
Number of subjects: 0
Study 11126695 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller explanatory trials or sub-studies
Number of subjects: 0
Study 8989012 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 micrograms/kg intravenous (i.v.) administration
Number of subjects: 9
Study 8989012 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 9
Study 8989012 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl during pain stimulation
Number of subjects: 9
Study 8452180 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg daily for 7 days
Number of subjects: 184
Study 8452180 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg daily for 14 days
Number of subjects: 184
Study 8452180 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol 50 mg/kg per day for 14 days
Number of subjects: 184
Study 3088648 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.0625, 0.25, 1.0, or 4.0 mg/kg)
Number of subjects: 7
Study 3088648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3088648 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 7
Study 31804005 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated grief therapy (CGT) with citalopram
Number of subjects: 394
Study 31804005 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated grief therapy (CGT) with placebo
Number of subjects: 394
Study 31804005 — intervention group
Group type: COMPARATOR
Intervention: Citalopram alone
Number of subjects: 394
Study 31804005 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 394
Study 30104147 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage ADM-assisted IBBR
Number of subjects: 142
Study 30104147 — intervention group
Group type: COMPARATOR
Intervention: Two-stage IBBR
Number of subjects: 142
Study 26893405 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Number of subjects: 116
Study 26893405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 24619608 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace treatment (Br group)
Number of subjects: 54
Study 24619608 — intervention group
Group type: COMPARATOR
Intervention: Observation alone (Ob group)
Number of subjects: 54
Study 21592809 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative device closure (group I)
Number of subjects: 252
Study 21592809 — intervention group
Group type: COMPARATOR
Intervention: Surgical closure (group II)
Number of subjects: 252
Study 19701691 — intervention group
Group type: EXPERIMENTAL
Intervention: Group BMP (Behavioral Modification Program)
Number of subjects: 44
Study 19701691 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 44
Study 16652130 — intervention group
Group type: EXPERIMENTAL
Intervention: bioactive supplement (n=57)
Number of subjects: 80
Study 16652130 — intervention group
Group type: COMPARATOR
Intervention: placebo (n=23)
Number of subjects: 80
Study 15827356 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain placed at the donor site for 24 hours
Number of subjects: 34
Study 15827356 — intervention group
Group type: COMPARATOR
Intervention: No drain at the donor site
Number of subjects: 34
Study 11834192 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ) 2.5 or 5.0 mg daily
Number of subjects: 10
Study 10207236 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially gastrectomized patients
Number of subjects: 2
Study 10207236 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched individuals not subjected to gastric surgery)
Number of subjects: 2
Study 7882472 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 41021
Study 7882472 — intervention group
Group type: EXPERIMENTAL
Intervention: Age < 45 years
Number of subjects: 41021
Study 7882472 — intervention group
Group type: EXPERIMENTAL
Intervention: Age > 75 years
Number of subjects: 41021
Study 7882472 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower systolic blood pressure
Number of subjects: 41021
Study 7882472 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Killip class
Number of subjects: 41021
Study 7882472 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated heart rate
Number of subjects: 41021
Study 7882472 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior infarction
Number of subjects: 41021
Study 2083044 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.3% triclosan and 2.0% copolymer in a 0.243% sodium fluoride/silica base
Number of subjects: 79
Study 2083044 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice containing 0.243% sodium fluoride in a silica base
Number of subjects: 79
Study 314777 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosage ampicillin (400 mg/kg per day)
Number of subjects: 172
Study 314777 — intervention group
Group type: COMPARATOR
Intervention: Low-dosage ampicillin (150 mg/kg per day)
Number of subjects: 172
Study 31888701 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of male-focused mobilization, community-based mobile HIV testing services, and a small incentive.
Number of subjects: 0
Study 31888701 — intervention group
Group type: EXPERIMENTAL
Intervention: Male-focused mobilization and testing strategies.
Number of subjects: 0
Study 28390417 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cognitive‐behavioral smoking cessation treatment
Number of subjects: 0
Study 28390417 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cognitive‐behavioral smoking cessation treatment plus behavioral activation
Number of subjects: 0
Study 28390417 — intervention group
Group type: COMPARATOR
Intervention: Three-month delayed treatment control group
Number of subjects: 0
Study 25837839 — intervention group
Group type: EXPERIMENTAL
Intervention: EP2006 (biosimilar filgrastim)
Number of subjects: 0
Study 25837839 — intervention group
Group type: COMPARATOR
Intervention: US‐approved originator filgrastim
Number of subjects: 0
Study 24103384 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring guided home-based training program
Number of subjects: 0
Study 24103384 — intervention group
Group type: COMPARATOR
Intervention: Regular centre-based training program
Number of subjects: 0
Study 21372490 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 30
Study 21372490 — intervention group
Group type: COMPARATOR
Intervention: Enteral Nutrition (EN)
Number of subjects: 30
Study 19335527 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding with skin-to-skin contact during immunization injections
Number of subjects: 120
Study 19335527 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine immunization without breast-feeding)
Number of subjects: 120
Study 16132779 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) therapy at a dose of 2000 U subcutaneously thrice weekly
Number of subjects: 40
Study 16132779 — intervention group
Group type: COMPARATOR
Intervention: Control group (parenteral iron only)
Number of subjects: 40
Study 12458867 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative arcuate keratotomy with phacoemulsification in the steeper meridian (arcuate keratotomy group)
Number of subjects: 34
Study 12458867 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification in the steeper meridian without arcuate keratotomy (control group)
Number of subjects: 34
Study 12458867 — intervention group
Group type: COMPARATOR
Intervention: Comparison between arcuate keratotomy group and control group
Number of subjects: 34
Study 10606486 — intervention group
Group type: EXPERIMENTAL
Intervention: Timeline Follow back method (TLFB)
Number of subjects: 95
Study 10606486 — intervention group
Group type: COMPARATOR
Intervention: Graduated frequency measure
Number of subjects: 95
Study 7489472 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 50 or 100 micrograms.kg‐1
Number of subjects: 56
Study 7489472 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 1.5 or 3.0 micrograms.kg‐1
Number of subjects: 56
Study 7489472 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 56
Study 2006566 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg daily for 30 days
Number of subjects: 10
Study 2006566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6754505 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin otic solution (0.3%)
Number of subjects: 55
Study 6754505 — intervention group
Group type: COMPARATOR
Intervention: Colistin-neomycin-hydrocortisone otic suspension (colistin 0.3%, neomycin 0.33%, hydrocortisone 1.0%)
Number of subjects: 55
Study 6754505 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 55
Study 30606151 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based hand rub (ABHR) used from birth to 3 months postnatally, guided by the 'Newborn Moments for Hand Hygiene in the Home' poster.
Number of subjects: 55
Study 30606151 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of the 'Newborn Moments for Hand Hygiene in the Home' poster.
Number of subjects: 55
Study 30606151 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptation of the WHO Moments for Hand Hygiene poster into a sticker format on the ABHR bottle.
Number of subjects: 55
Study 28728599 — intervention group
Group type: EXPERIMENTAL
Intervention: CinnoRA® (40 mg subcutaneous injections every other week)
Number of subjects: 136
Study 28728599 — intervention group
Group type: COMPARATOR
Intervention: Humira® (40 mg subcutaneous injections every other week)
Number of subjects: 136
Study 25738603 — intervention group
Group type: EXPERIMENTAL
Intervention: a‐tDCS of M1
Number of subjects: 12
Study 25738603 — intervention group
Group type: EXPERIMENTAL
Intervention: a‐tDCS of S1
Number of subjects: 12
Study 25738603 — intervention group
Group type: EXPERIMENTAL
Intervention: a‐tDCS of DLPFC
Number of subjects: 12
Study 25738603 — intervention group
Group type: COMPARATOR
Intervention: Sham a‐tDCS
Number of subjects: 12
Study 25738603 — intervention group
Group type: COMPARATOR
Intervention: No‐tDCS
Number of subjects: 12
Study 25738603 — intervention group
Group type: EXPERIMENTAL
Intervention: a‐tDCS of M1, S1, and DLPFC
Number of subjects: 12
Study 24835842 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy
Number of subjects: 1329
Study 24835842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1329
Study 21761403 — intervention group
Group type: EXPERIMENTAL
Intervention: WBI + RS
Number of subjects: 152
Study 21761403 — intervention group
Group type: COMPARATOR
Intervention: NR + WBI
Number of subjects: 152
Study 19752378 — intervention group
Group type: EXPERIMENTAL
Intervention: Homograft aortic root replacement
Number of subjects: 166
Study 19752378 — intervention group
Group type: COMPARATOR
Intervention: Freestyle aortic root replacement
Number of subjects: 166
Study 17464615 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided injection
Number of subjects: 20
Study 17464615 — intervention group
Group type: COMPARATOR
Intervention: Blind injection
Number of subjects: 20
Study 15220729 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation (AM group)
Number of subjects: 86
Study 15220729 — intervention group
Group type: COMPARATOR
Intervention: Conjunctival autograft (CG group)
Number of subjects: 86
Study 12176948 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg monotherapy for 2 years
Number of subjects: 327
Study 9639238 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular gum
Number of subjects: 20
Study 9639238 — intervention group
Group type: COMPARATOR
Intervention: Gum base
Number of subjects: 20
Study 7857504 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg of hypericum per day combined with bright light therapy (3000 lux)
Number of subjects: 20
Study 7857504 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg of hypericum per day combined with dim light therapy (< 300 lux)
Number of subjects: 20
Study 2766723 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 micrograms of gestodene combined with 30 micrograms ethinylestradiol as tablet
Number of subjects: 6
Study 2766723 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 micrograms of gestodene combined with 30 micrograms ethinylestradiol as coated tablet
Number of subjects: 6
Study 791872 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoxymethasone
Number of subjects: 50
Study 791872 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone valerate
Number of subjects: 50
Study 30623857 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 69
Study 30623857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 27889299 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 173
Study 27889299 — intervention group
Group type: COMPARATOR
Intervention: CNI
Number of subjects: 173
Study 25265887 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate parenteral sedation and paracervical block
Number of subjects: 56
Study 25265887 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 56
Study 22816679 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt beverage providing 4 g of phytosterols per day
Number of subjects: 108
Study 22816679 — intervention group
Group type: COMPARATOR
Intervention: Yogurt beverage without phytosterols (placebo)
Number of subjects: 108
Study 21226129 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 8
Study 18632210 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking-related weight control expectancies
Number of subjects: 755
Study 17542117 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education for 2 months (face-to-face sessions, group discussions, pamphlets)
Number of subjects: 60
Study 17542117 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutrition education)
Number of subjects: 60
Study 14677218 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor training; motor learning training with imagery; electrical stimulation (alone or combined with biofeedback); engaging in repetitive, novel tasks
Number of subjects: 0
Study 14677218 — intervention group
Group type: EXPERIMENTAL
Intervention: Careful handling; electrical stimulation; movement with elevation; strapping; avoidance of overhead pulleys
Number of subjects: 0
Study 11061779 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) program (n = 16)
Number of subjects: 32
Study 11061779 — intervention group
Group type: COMPARATOR
Intervention: Control (C) program (n = 16)
Number of subjects: 32
Study 8899078 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose polyester (50 g as a single drink)
Number of subjects: 0
Study 1900605 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Rambo meatoplasty during translabyrinthine tumor removal
Number of subjects: 50
Study 1900605 — intervention group
Group type: COMPARATOR
Intervention: Obstruction of the tympanic orifice of the eustachian tube through the facial recess
Number of subjects: 50
Study 6679229 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (IV administration, bolus of 0.075 mg/kg up to 5 mg)
Number of subjects: 17
Study 6679229 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (IV administration)
Number of subjects: 17
Study 6679229 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral drug therapy
Number of subjects: 17
Study 31380699 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-enhanced behavior therapy for TTM
Number of subjects: 0
Study 31380699 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation and supportive control condition
Number of subjects: 0
Study 27933703 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP for 3 months
Number of subjects: 90
Study 27933703 — intervention group
Group type: COMPARATOR
Intervention: Subtherapeutic CPAP for 3 months
Number of subjects: 90
Study 27933703 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 90
Study 27933703 — intervention group
Group type: COMPARATOR
Intervention: Subtherapeutic CPAP
Number of subjects: 90
Study 25721551 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 19
Study 25721551 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 19
Study 24858834 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) mouth rinse
Number of subjects: 10
Study 24858834 — intervention group
Group type: COMPARATOR
Intervention: Taste-matched placebo (PLA) mouth rinse
Number of subjects: 10
Study 23049087 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects at 20 Hz
Number of subjects: 117
Study 23049087 — intervention group
Group type: EXPERIMENTAL
Intervention: Stargardt's disease at 20 Hz
Number of subjects: 117
Study 23049087 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary open‐angle glaucoma at 20 Hz
Number of subjects: 117